XORTX Therapeutics Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Cover
- Cover
Financial Statements
Notes to Financial Statements
Accounting Policies
- Material Accounting policies (Policies)
Notes Tables
Notes Details

Commitments (Tables)

Commitments (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of long-term arrangements with commitments that are not recognized as liabilities


	December 31,	December 31,
	2023	2022
	$	$
Management services – officers	321,000	441,754¹

¹The former CFO of the Company had a termination clause whereby he was entitled to the equivalent of 12 times his then current monthly salary which as of December 31, 2022, equated to an annual salary of CAD $192,000.